GB9802543D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB9802543D0
GB9802543D0 GBGB9802543.0A GB9802543A GB9802543D0 GB 9802543 D0 GB9802543 D0 GB 9802543D0 GB 9802543 A GB9802543 A GB 9802543A GB 9802543 D0 GB9802543 D0 GB 9802543D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9802543.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB9802543.0A priority Critical patent/GB9802543D0/en
Publication of GB9802543D0 publication Critical patent/GB9802543D0/en
Priority to DK06075363.9T priority patent/DK1659179T3/en
Priority to AT06075363T priority patent/ATE513042T1/en
Priority to BRPI9907691-8A priority patent/BR9907691B1/en
Priority to EP06075362A priority patent/EP1659178B1/en
Priority to KR1020067008476A priority patent/KR100824105B1/en
Priority to EP05076599A priority patent/EP1584685B1/en
Priority to SI9931044T priority patent/SI1659178T1/en
Priority to SI9931053T priority patent/SI1584685T1/en
Priority to DK05076599.9T priority patent/DK1584685T3/en
Priority to SI9931061T priority patent/SI1659179T1/en
Priority to EP06075363A priority patent/EP1659179B1/en
Priority to DE69942214T priority patent/DE69942214D1/en
Priority to CNB998046043A priority patent/CN1227360C/en
Priority to ES06075363T priority patent/ES2367998T3/en
Priority to IL13744299A priority patent/IL137442A0/en
Priority to ES99907476T priority patent/ES2255248T3/en
Priority to KR1020007008550A priority patent/KR100633212B1/en
Priority to AU27220/99A priority patent/AU737337B2/en
Priority to CA2584482A priority patent/CA2584482C/en
Priority to DE69943359T priority patent/DE69943359D1/en
Priority to ES05076599T priority patent/ES2362783T3/en
Priority to HU0102639A priority patent/HU228467B1/en
Priority to AT05076599T priority patent/ATE505542T1/en
Priority to PT06075362T priority patent/PT1659178E/en
Priority to PT06075363T priority patent/PT1659179E/en
Priority to PT05076599T priority patent/PT1584685E/en
Priority to DE69929310T priority patent/DE69929310T2/en
Priority to PCT/EP1999/000660 priority patent/WO1999040188A2/en
Priority to EP99907476A priority patent/EP1053325B1/en
Priority to CZ20060442A priority patent/CZ298347B6/en
Priority to PL342852A priority patent/PL203645B1/en
Priority to DK99907476T priority patent/DK1053325T3/en
Priority to AT99907476T priority patent/ATE315088T1/en
Priority to SI9930879T priority patent/SI1053325T1/en
Priority to CA2319309A priority patent/CA2319309C/en
Priority to ES06075362T priority patent/ES2342416T3/en
Priority to PT99907476T priority patent/PT1053325E/en
Priority to DK06075362.1T priority patent/DK1659178T3/en
Priority to NZ506086A priority patent/NZ506086A/en
Priority to TR2000/02284T priority patent/TR200002284T2/en
Priority to CZ20002869A priority patent/CZ298364B6/en
Priority to JP2000530602A priority patent/JP4768121B2/en
Priority to AT06075362T priority patent/ATE462788T1/en
Priority to ARP990100475A priority patent/AR018064A1/en
Priority to ZA9900872A priority patent/ZA99872B/en
Priority to TW088102224A priority patent/TWI238853B/en
Priority to SA99200126A priority patent/SA99200126B1/en
Priority to IL137442A priority patent/IL137442A/en
Priority to NO20003958A priority patent/NO328507B1/en
Priority to HK01103307A priority patent/HK1033838A1/en
Priority to HK06101448.0A priority patent/HK1083026A1/en
Priority to HK06111054.4A priority patent/HK1093521A1/en
Priority to HK06111055.3A priority patent/HK1093522A1/en
Priority to CY20061100310T priority patent/CY1105685T1/en
Priority to IL179010A priority patent/IL179010A0/en
Priority to IL188875A priority patent/IL188875A/en
Priority to NO20091665A priority patent/NO331719B1/en
Priority to JP2009120409A priority patent/JP2009201510A/en
Priority to US12/640,306 priority patent/US8097257B2/en
Priority to US12/722,691 priority patent/US8044183B2/en
Priority to CY20101100509T priority patent/CY1110180T1/en
Priority to CY20111100663T priority patent/CY1111672T1/en
Priority to CY20111100885T priority patent/CY1111831T1/en
Priority to US13/324,509 priority patent/US8597656B2/en
Ceased legal-status Critical Current

Links

GBGB9802543.0A 1998-02-05 1998-02-05 Vaccine Ceased GB9802543D0 (en)

Priority Applications (65)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine
DK06075363.9T DK1659179T3 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the MAGE family and nucleic acid sequences encoding them used to prepare fusion proteins and vaccine compositions
AT06075363T ATE513042T1 (en) 1998-02-05 1999-02-02 TUMOR-ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY,NUCLIC ACID SEQUENCES ENCODING SAME FOR PRODUCING FUSION PROTEINS AND VACCINATION COMPOSITIONS
BRPI9907691-8A BR9907691B1 (en) 1998-02-05 1999-02-02 derived from tumor-associated antigen and mage family antigen, nucleic acid sequence, coding for them, their uses in vaccine preparation, process for vaccine and vaccine production.
EP06075362A EP1659178B1 (en) 1998-02-05 1999-02-02 A process for the purification or production of a MAGE protein
KR1020067008476A KR100824105B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP05076599A EP1584685B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
SI9931044T SI1659178T1 (en) 1998-02-05 1999-02-02 A process for the purification or production of a MAGE protein
SI9931053T SI1584685T1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with T-helper epitopes and of compositions for vaccination
DK05076599.9T DK1584685T3 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the Mage family, used to prepare fusion proteins with T helper epitopes and vaccine compositions
SI9931061T SI1659179T1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP06075363A EP1659179B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
DE69942214T DE69942214D1 (en) 1998-02-05 1999-02-02 Process for purifying or producing the MAGE protein
CNB998046043A CN1227360C (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from MAGE family, and nucleic acid sequence encoding them
ES06075363T ES2367998T3 (en) 1998-02-05 1999-02-02 ANTIGEN DERIVATIVES ASSOCIATED WITH TUMORS OF THE MAGE FAMILY, AND NUCLEIC ACID SEQUENCES CODING THEM, USED FOR THE PREPARATION OF FUSION PROTEINS AND COMPOSITIONS FOR VACCINATION.
IL13744299A IL137442A0 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
ES99907476T ES2255248T3 (en) 1998-02-05 1999-02-02 DERIVATIVES OF ANTIGENS ASSOCIATED TO TUMOR OF THE MAGE FAMILY, AND SEQUENCES OF NUCLEIC ACIDS THAT CODIFY THEM, USED FOR THE PREPARATION OF FUSION PROTEINS AND COMPOSITIONS FOR VACCINES.
KR1020007008550A KR100633212B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
AU27220/99A AU737337B2 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
CA2584482A CA2584482C (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
DE69943359T DE69943359D1 (en) 1998-02-05 1999-02-02 Mage family tumor-associated antigenic derivatives, for the preparation of fusion proteins with T-helper epitopes and compositions for vaccination
ES05076599T ES2362783T3 (en) 1998-02-05 1999-02-02 ANTIGEN DERIVATIVES ASSOCIATED WITH TUMORS OF THE MAGE FAMILY, USED FOR THE PREPARATION OF FUSION PROTEINS WITH TITLE OF AUXILIARY T AND COMPOSITIONS FOR VACCINATION.
HU0102639A HU228467B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
AT05076599T ATE505542T1 (en) 1998-02-05 1999-02-02 TUMOR-ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY FOR THE PRODUCTION OF FUSION PROTEINS WITH T-HELPER EPITOPES AND COMPOSITIONS FOR VACCINATION
PT06075362T PT1659178E (en) 1998-02-05 1999-02-02 A process for the purification or production of a mage protein
PT06075363T PT1659179E (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
PT05076599T PT1584685E (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
DE69929310T DE69929310T2 (en) 1998-02-05 1999-02-02 TUMOR ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY, NUCLEIC ACID SEQUENCES THAT CODE FOR THE PREPARATION OF FUSION PROTEINS AND COMPOSITIONS FOR VACCINATION
PCT/EP1999/000660 WO1999040188A2 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
EP99907476A EP1053325B1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
CZ20060442A CZ298347B6 (en) 1998-02-05 1999-02-02 Fusion protein of MAGE family, nucleic acid sequence encoding such protein, vector, host cell, vaccine and use of such fuse protein for preparing the vaccine
PL342852A PL203645B1 (en) 1998-02-05 1999-02-02 MAGE family tumor-associated antigen derivative and use, nucleic acid sequence and use thereof, vector, host cell, vaccine, method of purifying MAGE protein or a derivative thereof, and method of making a vaccine
DK99907476T DK1053325T3 (en) 1998-02-05 1999-02-02 Tumor-associated antigenic derivatives of the gastric family and encoding nucleic acid sequences used for the preparation of fusion proteins and preparations for vaccination
AT99907476T ATE315088T1 (en) 1998-02-05 1999-02-02 TUMOR-ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY, NUCLEIC ACID SEQUENCES THAT CODE FOR THE PRODUCTION OF FUSION PROTEINS AND COMPOSITIONS FOR VACCINATION
SI9930879T SI1053325T1 (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
CA2319309A CA2319309C (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
ES06075362T ES2342416T3 (en) 1998-02-05 1999-02-02 PROCEDURE OF PURIFICATION OR PRODUCTION OF A PROTEIN MAGE.
PT99907476T PT1053325E (en) 1998-02-05 1999-02-02 ANTIGEN DERIVATIVES ASSOCIATED WITH MAGE FAMILY TUMORS, AND SEQUENCES OF NUCLEIC ACIDS THAT ENCODE THEM, USED FOR THE PREPARATION OF FUSAO PROTEINS AND VACCINATION COMPOUNDS.
DK06075362.1T DK1659178T3 (en) 1998-02-05 1999-02-02 Process for the purification or preparation of a MAGE protein
NZ506086A NZ506086A (en) 1998-02-05 1999-02-02 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins, antigens comprising derivatised thiol residues and of compositions for vaccination
TR2000/02284T TR200002284T2 (en) 1998-02-05 1999-02-02 Tumor related tumor derivatives from the Mage family
CZ20002869A CZ298364B6 (en) 1998-02-05 1999-02-02 Antigen derivatives associated with tumors of MAGE family a nucleic acid sequence encoding these derivatives, their use for preparing fusion proteins and preparations for vaccination
JP2000530602A JP4768121B2 (en) 1998-02-05 1999-02-02 Tumor associated antigens from the MAGE family and the nucleic acid sequences encoding them, the use of fusion proteins and for the preparation of compositions for vaccination
AT06075362T ATE462788T1 (en) 1998-02-05 1999-02-02 METHOD FOR PURIFYING OR PRODUCING MAGE PROTEIN
ARP990100475A AR018064A1 (en) 1998-02-05 1999-02-04 FUSION PROTEIN WHICH CONSISTS OF AN ANTIGEN ASSOCIATED WITH TUMORS DERIVED FROM THE MAGE FAMILY, SEQUENCE OF NUCLEIC ACID THAT CODIFIES IT, VECTOR THAT UNDERSTANDS IT, CELLULATES A CUSTOMER THAT CANNOT GENERATE A COMPLETE INDIVIDUAL TRANSFORMED WITH ANY DUCT , HIS
ZA9900872A ZA99872B (en) 1998-02-05 1999-02-04 Vaccine.
TW088102224A TWI238853B (en) 1998-02-05 1999-02-12 Tumour-associated antigen derivative from the MAGE family, and the nucleic acid, vector, host cell, vaccine, and preparation thereof
SA99200126A SA99200126B1 (en) 1998-02-05 1999-05-16 Vaccines
IL137442A IL137442A (en) 1998-02-05 2000-07-21 Tumor-associated antigen derivatives from the mage family and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
NO20003958A NO328507B1 (en) 1998-02-05 2000-08-04 Tumor-associated antigen derivatives from the MAGE family, vaccine containing them and their use for the preparation of vaccine, as well as methods for purifying the antigen derivatives and preparing the vaccine
HK01103307A HK1033838A1 (en) 1998-02-05 2001-05-11 Tumor-asociated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and ofcompositions for vaccination
HK06101448.0A HK1083026A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
HK06111054.4A HK1093521A1 (en) 1998-02-05 2001-05-11 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
HK06111055.3A HK1093522A1 (en) 1998-02-05 2001-05-11 A process for the purification or production of a mage protein
CY20061100310T CY1105685T1 (en) 1998-02-05 2006-03-07 TUMOR-ASSOCIATED ANTIGENS OF THE MAGE FAMILY, AND NUCLEIC ACID SEQUENCES ENCODING THEM, USED IN THE PREPARATION OF FUSION PROTEINS AND COMPOSITIONS FOR VACCINATION
IL179010A IL179010A0 (en) 1998-02-05 2006-11-02 Mage fusion protein comprising mage antigen and a fusion partner, and nucleic acid sequences encoding them, and uses thereof
IL188875A IL188875A (en) 1998-02-05 2008-01-17 Process for the purification or production of a mage protein and the use of the protein for the production of a vaccine
NO20091665A NO331719B1 (en) 1998-02-05 2009-04-27 Process for purifying or preparing a MAGE protein and preparing a vaccine
JP2009120409A JP2009201510A (en) 1998-02-05 2009-05-18 Tumor-associated antigen from mage family, and nucleic acid sequence encoding them, and use for preparation of fusion protein and of composition for vaccination
US12/640,306 US8097257B2 (en) 1998-02-05 2009-12-17 MAGE3 polypeptides
US12/722,691 US8044183B2 (en) 1998-02-05 2010-03-12 Process for the production of immunogenic compositions
CY20101100509T CY1110180T1 (en) 1998-02-05 2010-06-10 METHOD FOR CLEANING OR PRODUCING A PROTEIN MAGE
CY20111100663T CY1111672T1 (en) 1998-02-05 2011-07-08 ANTIGEN PRODUCERS MADE TO THE MAGE FAMILY VOLUME USED FOR PREPARATION OF PRIMARY EFFECTIVENESS
CY20111100885T CY1111831T1 (en) 1998-02-05 2011-09-14 MAG FAMILY-DIGITAL ANTIGEN-DERIVATIVES FROM MAGE FAMILY AND NUCLEAR ACID SEQUENCES CODING THESE, WHILE USING THEM
US13/324,509 US8597656B2 (en) 1998-02-05 2011-12-13 Process for the production of immunogenic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9802543.0A GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine

Publications (1)

Publication Number Publication Date
GB9802543D0 true GB9802543D0 (en) 1998-04-01

Family

ID=10826561

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9802543.0A Ceased GB9802543D0 (en) 1998-02-05 1998-02-05 Vaccine

Country Status (3)

Country Link
ES (2) ES2367998T3 (en)
GB (1) GB9802543D0 (en)
ZA (1) ZA99872B (en)

Also Published As

Publication number Publication date
ES2367998T3 (en) 2011-11-11
ES2362783T3 (en) 2011-07-13
ZA99872B (en) 2000-08-04

Similar Documents

Publication Publication Date Title
IL140094A0 (en) Vaccine
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
PL341761A1 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
PL343065A1 (en) Vaccine composition
HUP0105392A3 (en) Enhanced vaccines
GB9822714D0 (en) Vaccines
PL344519A1 (en) Vaccine
GB9801870D0 (en) Vaccine composition
GB9807805D0 (en) Vaccine
GB9820956D0 (en) Vaccine
GB9821821D0 (en) Schistomiasis vaccine
GB9809958D0 (en) Vaccine
GB9805961D0 (en) Vaccine
GB9802544D0 (en) Vaccine
GB9822712D0 (en) Vaccine
GB9822709D0 (en) Vaccine
GB9822703D0 (en) Vaccine
GB9812773D0 (en) Vaccine
GB9802650D0 (en) Vaccine
GB9812228D0 (en) Vaccine
GB9805958D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)